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Correspondence Frequency and Pattern of Left Ventricular Dysfunction
in Potential Heart Donors
Implications Regarding Use of
Dysfunctional Hearts for Successful TransplantationTo the Editor: Cardiac transplantation is a widely accepted treat-
ent for patients with advanced heart failure. Unfortunately only
in 8 hearts offered for donation is accepted for transplantation
1). Some donor hearts may be rejected due to left ventricular
ystolic dysfunction (LVSD) noted on initial assessment (2). In our
study, we sought to evaluate the frequency and pattern of LVSD as
well as to determine change in left ventricular (LV) function over
time in such patients.
Acute brain injury (ABI) is the most frequent cause of death
in potential donors, and LVSD is a well-reported abnormality
in these patients (3– 6). Systolic dysfunction has an incidence of
up to 45% in patients with ABI and other neurological injuries
(2,4,6,7). Left ventricular dysfunction in such a setting is often
reversible over time and is postulated to be due to transient
catecholamine surge that accompanies ABI, rather than coro-
nary artery disease (1– 8). We report a single-center series
assessing the frequency and pattern of LVSD in potential heart
donors.
Thirty-four adult organ donors were evaluated for LVSD by
echocardiography or angiography. The pattern of predominant
wall motion abnormality was noted at baseline and, when available,
on serial examinations. We also reviewed information regarding
cause of ABI and pressor usage.
Our data revealed a young cohort (mean age of 38 years)
consisting of 22 males and 12 females. The most common causes
of death were gunshot wounds to the head followed by motor
vehicle accidents. the majority of potential donors, (23 of 34, 68%)
had normal LV function. Patients with LVSD (11 of 34, 32%)
could be classified into 4 distinct groups based on the anatomical
location of the dysfunction: apical (2 of 11), basal (3 of 11),
Summary of 11 Potential Donors With Cardiac DysfunctionTable 1 Summary of 11 Potential Donors With Cardiac Dysfunction
Age
(Yrs) Sex Cause
Dysfunction
Pattern
Peak
Troponin I
31 Male Head trauma Diffuse global 0.55
46 Male Drug overdose Diffuse global 9.57
25 Male Vehicle accident Diffuse global 0.36
20 Male Gun shot head Basal 1.55
45 Female Drug overdose Diffuse global 2.92
20 Male Gun shot head Diffuse global 0.73
55 Female SAH Basal NA
18 Male Gun shot head Midcavity 4.14
63 Male SAH Basal 3.22
51 Female Cardiac arrest Apical 0.32
23 Male Gun shot head Apical NACK-MB  creatine kinase–myocardial band; EF  ejection fraction; NA  not available; SAH  subarachmidcavity (1 of 11), and diffuse global (5 of 11). Five patients
(45%) underwent repeat assessment of their LVSD, and all
demonstrated improved systolic function. Furthermore, in 3 pa-
tients, the ejection fraction (EF) normalized. As seen in Table 1,
the improvement was seen as early as 3 h after the initial
assessment. Data on pressor usage revealed that exogenous cat-
echolamines did not contribute to worsening or improvement in
LV function.
In our series, we noted that nearly one-third of the potential
donors had LVSD on initial assessment. In those with
follow-up studies, LVSD improved in all regardless of type of
initial pattern of dysfunction. Furthermore, in 3 patients, there
was a complete normalization of LV systolic function. Unfor-
tunately, only 1 of the 11 donors with LVSD was accepted for
transplant. The patient with an initial EF of 30% (last patient
in Table1) had assessment 10 h later indicating improvement in
EF, and the heart was procured. An echocardiogram performed
immediately after transplant showed an EF of 60%. Subsequent
examinations demonstrated that normal LV systolic function
was maintained.
It is well known that a catecholamine surge is seen in patients
with ABI (1,3–7,9). Studies have indicated that serum levels of
catecholamines correlate with the severity of neurological injury
and outcome (5). This catecholamine excess is thought to induce
LVSD in susceptible patients (1,3,5,6,8). Autopsy data have
confirmed myocardial band necrosis, also known as myocytolysis
without ischemic necrosis (3,6) in patients suffering from ABI.
This finding, in patients who had new LVSD after an ABI, is
consistent with catecholamine toxicity (1,3,4,6). At a cellular level,
adrenergic hyperstimulation is thought to lead to pathological
B Pressors
Initial
EF
Repeat
EF
Repeat EF
Time Frame
Desmopressin, phenylephrine 34% 45% 10 h
Dopamine, norepinephrine 40%
Dopamine, phenylephrine 25% 60% 10 h
Norepinephrine 45%
Dopamine, phenylephrine 12%
Desmopressin 30%
Desmopressin, phenylephrine 43%
No pressors 35% 41% 3 h
Desmopressin 40%
Desmopressin 35% 56% 36 h
Phenylephrine 30% 60% 10 hPeak
CK-M
7.0
27.6
38.9
22.0
6.5
33.9
14.7
14.1
17.6
14.1
NAnoid hemorrhage.
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July 17, 2012:235–41myocyte calcium influx though myocardial 3=,5=-cyclic adenosine
monophosphate production, leading to adenosine triphosphate
depletion (1,4,10).
The catecholamine-induced cardiac dysfunction, often termed
“neurogenic stress cardiomyopathy,” bears many similarities to
Takosubo cardiomyopathy (4,7,8). Takosubo cardiomyopathy is
thought to be induced by catecholamine excess, and manifests with
apical wall motion abnormalities that do not correlate with a
coronary distribution (3,4,6). In contrast to classic Takosubo
cardiomyopathy, neurogenic stress cardiomyopathy most fre-
quently presents with global hypokinesis (4). In our study, the
global pattern of LVSD (45%) was predominant, followed by
basal/mid cavity pattern (36%). The apical pattern constituted only
18% of our patients.
It has been previously thought that patient with neurogenic
stress cardiomyopathy normalize their LV function within days to
weeks (1). In potential donors with ABI, waiting for such time for
normalization of LV function will be unreasonable. In our study,
the repeat assessment of LV function ranged from 3 to 36 h. Our
findings suggest that an initial examination showing LVSD should
not exclude a potential heart donor. Serial assessment should be
undertaken in all potential donors who have ABI before excluding
cardiac procurement. Reassessment over time and possibly tempo-
rizing organ procurement may permit LV function to improve
enough that procurement is reasonable, and will increase the pool
of hearts available for transplantation.
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Letters to the Editor
Does New Onset Atrial
Fibrillation Have a True
Impact on the Incidence of
Stroke After Transcatheter
Aortic Valve Implantation?
We read with interest the paper by Amat-Santos et al. (1)
describing the importance of new-onset atrial fibrillation (NOAF)
after transcatheter aortic valve implantation (TAVI). They de-
scribe an association between NOAF and embolic events (EE),
suggesting that NOAF may be a mechanism for late neurological
events after TAVI. However, we believe that the adjudication of
the EE overestimates the association and impairs the generation of
a hypothesis of causality.
The association of TAVI with NOAF and EE is biologically
plausible following Bradford Hill’s classic causality criteria (2). But
nother criterion is temporality: the cause must precede the effect.
onetheless, Patient #4 and Patient #6 from Table 4 (1) had the
mbolic event 48 h and 18 days, respectively, before the NOAF
pisode (1). Therefore, those EE should not be attributed to NOAF.
atient #10 from Table 4 (1) had a stroke 645 days after TAVI (640
ays after NOAF), and moreover, was under warfarin treatment with
n international normalized ratio of 2.2 at hospital admission. Thus,
t is doubtful that this stroke may have a causal relation to the TAVI
rocedure.
Besides the statistical limitation of a low number of events, if we
emove these 3 events from the NOAF group, there are 3
emaining strokes at 30 days (incidence 6.8% vs. 3.2% in the
o-NOAF group; odds ratio: 2.22, 95% confidence interval: 0.43
o 11.47, unadjusted p  0.330). The incidence of stroke/systemic
mbolism at 30 days would be 9.1% versus 3.2% (odds ratio: 3.03,
5% confidence interval: 0.65 to 14.18, unadjusted p  0.141).
hus, the incidence of EE at 30 days does not reach statistical
ignificance, and has a poor clinical and causal significance. The
umulative incidence at follow-up would only add 1 event with
ncertain causal relationship to TAVI.
Stroke is a major concern in TAVI, accounting for as many as
1% of deaths at 1 month (3). In a smaller series with 91%
ransfemoral TAVI, our group found 6% NOAF, with no impact
n EE (6%) or mortality during a mean follow-up of 11 months
4). Left atrial appendage might be a source of thrombus in NOAF
fter TAVI, but is still unconfirmed. It would be revealing if the
uthors provided information about transesophageal echocardiog-
aphy. The presence of thrombus in the left atrial appendage
efore or during the TAVI procedure could contribute to support
he AF hypothesis as a mechanism of the late embolic events.
